Drug Profile
Lixisenatide - Sanofi
Alternative Names: Adlyxin; AQVE-10010; AVE-0010; AVE0100; Lyxumia; ZP-10; ZP10A peptideLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Zealand Pharma
- Developer Sanofi; sanofi-aventis
- Class Antihyperglycaemics; Peptides
- Mechanism of Action Glucagon like peptide 1 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Type 2 diabetes mellitus
- Phase II Parkinson's disease; Type 1 diabetes mellitus
Most Recent Events
- 28 Jan 2022 No recent reports of development identified for phase-I development in Type-2-diabetes-mellitus(In adolescents, In children) in Mauritius (SC, Immediate release)
- 28 Jan 2022 No recent reports of development identified for phase-I development in Type-2-diabetes-mellitus(In adolescents, In children) in Mexico (SC, Immediate release)
- 28 Jan 2022 No recent reports of development identified for phase-I development in Type-2-diabetes-mellitus(In adolescents, In children) in South Africa (SC, Immediate release)